Fig. 6. Caspase inhibition prevents Fas-L-induced apoptosis but not Fas-L-induced proliferation of ASCs.

ASCs (P2-3) were treated for 4 days with the Fas-L, caspase inhibitor Z-VAD-fmk or both. Sub-G1 proportions a and c and cell numbers (b) were determined by PI cell cycle flow cytometry analysis and standard cell counts, respectively. The experiment was repeated three times using cells from three independent patients. Data are presented as the mean ± standard deviation. d Representative images of ASCs under the different conditions are shown